The navigation below allows you to jump to any table or figure within the SEER Cancer Statistics Review.
- First select the CSR Section, then a Table/Figure from that section.
- Use the Submit button to view the table or figure. You will have options to download a printer-friendly version (PDF) or the data table (CSV) as well.
To learn more about the Cancer Statistics Review and the statistics presented in this report, refer to the About the CSR (PDF, 524 KB) and Technical Notes (PDF, 756 KB) pages.
Download and Print: Download Printer-friendly PDF Download data
Table 28.13
| Age at Diagnosis | Primary Site | Rate | Number of Cases |
|---|---|---|---|
| Age <1 | All Sites | 23.6 | 1,341 |
| Leukemia | 4.8 | 271 | |
| Acute Lymphocytic Leukemia | 2.0 | 112 | |
| Brain and ONSd | 3.7 | 213 | |
| Soft Tissue | 3.5 | 198 | |
| Eye and Orbit | 3.2 | 181 | |
| Other Endocrine | 2.6 | 146 | |
| Age 1 | All Sites | 21.5 | 1,233 |
| Leukemia | 6.7 | 382 | |
| Acute Lymphocytic Leukemia | 4.2 | 243 | |
| Brain and ONSd | 4.2 | 241 | |
| Kidney and Renal Pelvis | 2.1 | 122 | |
| Soft Tissue | 1.7 | 99 | |
| Eye and Orbit | 1.5 | 87 | |
| Age 2 | All Sites | 24.4 | 1,413 |
| Leukemia | 10.3 | 598 | |
| Acute Lymphocytic Leukemia | 9.1 | 528 | |
| Brain and ONSd | 4.8 | 275 | |
| Kidney and Renal Pelvis | 2.2 | 128 | |
| Eye and Orbit | 1.5 | 84 | |
| Soft Tissue | 1.4 | 82 | |
| Age 3 | All Sites | 23.4 | 1,353 |
| Leukemia | 11.5 | 664 | |
| Acute Lymphocytic Leukemia | 10.3 | 597 | |
| Brain and ONSd | 4.1 | 236 | |
| Kidney and Renal Pelvis | 2.1 | 122 | |
| Other Endocrine | 1.3 | 73 | |
| Soft Tissue | 1.1 | 62 | |
| Age 4 | All Sites | 18.1 | 1,059 |
| Leukemia | 8.5 | 495 | |
| Acute Lymphocytic Leukemia | 7.6 | 442 | |
| Brain and ONSd | 3.6 | 212 | |
| Kidney and Renal Pelvis | 1.4 | 81 | |
| Soft Tissue | 1.0 | 57 | |
| Non-Hodgkin Lymphoma | 0.8 | 48 | |
| Age 5 | All Sites | 14.4 | 842 |
| Leukemia | 5.7 | 335 | |
| Acute Lymphocytic Leukemia | 4.8 | 284 | |
| Brain and ONSd | 3.8 | 223 | |
| Non-Hodgkin Lymphoma | 1.0 | 59 | |
| Kidney and Renal Pelvis | 1.0 | 57 | |
| Soft Tissue | 0.6 | 34 | |
| Age 6 | All Sites | 14.1 | 821 |
| Leukemia | 4.9 | 288 | |
| Acute Lymphocytic Leukemia | 4.3 | 252 | |
| Brain and ONSd | 4.0 | 233 | |
| Non-Hodgkin Lymphoma | 1.2 | 70 | |
| Kidney and Renal Pelvis | 0.8 | 47 | |
| Bones and Joints | 0.6 | 35 | |
| Age 7 | All Sites | 11.6 | 674 |
| Leukemia | 3.9 | 225 | |
| Acute Lymphocytic Leukemia | 3.3 | 190 | |
| Brain and ONSd | 3.5 | 201 | |
| Non-Hodgkin Lymphoma | 1.0 | 60 | |
| Soft Tissue | 0.8 | 44 | |
| Bones and Joints | 0.5 | 29 | |
| Age 8 | All Sites | 11.4 | 662 |
| Leukemia | 3.4 | 196 | |
| Acute Lymphocytic Leukemia | 2.9 | 171 | |
| Brain and ONSd | 3.2 | 188 | |
| Non-Hodgkin Lymphoma | 1.2 | 67 | |
| Bones and Joints | 0.6 | 36 | |
| Soft Tissue | 0.6 | 35 | |
| Age 9 | All Sites | 12.0 | 693 |
| Leukemia | 3.7 | 212 | |
| Acute Lymphocytic Leukemia | 2.9 | 165 | |
| Brain and ONSd | 2.9 | 169 | |
| Non-Hodgkin Lymphoma | 1.5 | 84 | |
| Bones and Joints | 1.0 | 55 | |
| Hodgkin Lymphoma | 0.7 | 40 | |
| Age 10 | All Sites | 11.8 | 688 |
| Leukemia | 3.1 | 182 | |
| Acute Lymphocytic Leukemia | 2.4 | 141 | |
| Brain and ONSd | 2.8 | 163 | |
| Non-Hodgkin Lymphoma | 1.2 | 68 | |
| Bones and Joints | 1.0 | 61 | |
| Soft Tissue | 0.8 | 46 | |
| Age 11 | All Sites | 11.9 | 699 |
| Brain and ONSd | 2.9 | 167 | |
| Leukemia | 2.8 | 161 | |
| Acute Lymphocytic Leukemia | 1.8 | 108 | |
| Bones and Joints | 1.2 | 73 | |
| Non-Hodgkin Lymphoma | 1.2 | 71 | |
| Hodgkin Lymphoma | 0.7 | 42 | |
| Age 12 | All Sites | 13.8 | 814 |
| Leukemia | 3.3 | 195 | |
| Acute Lymphocytic Leukemia | 2.3 | 136 | |
| Brain and ONSd | 2.8 | 163 | |
| Bones and Joints | 1.6 | 93 | |
| Non-Hodgkin Lymphoma | 1.3 | 78 | |
| Hodgkin Lymphoma | 1.2 | 71 | |
| Age 13 | All Sites | 14.9 | 882 |
| Leukemia | 3.4 | 202 | |
| Acute Lymphocytic Leukemia | 2.1 | 127 | |
| Brain and ONSd | 2.4 | 140 | |
| Bones and Joints | 1.7 | 103 | |
| Hodgkin Lymphoma | 1.5 | 88 | |
| Non-Hodgkin Lymphoma | 1.4 | 85 | |
| Age 14 | All Sites | 16.5 | 979 |
| Leukemia | 3.7 | 220 | |
| Acute Lymphocytic Leukemia | 2.4 | 145 | |
| Brain and ONSd | 2.6 | 155 | |
| Hodgkin Lymphoma | 1.7 | 99 | |
| Non-Hodgkin Lymphoma | 1.5 | 92 | |
| Bones and Joints | 1.5 | 88 | |
| Age 15 | All Sites | 19.1 | 1,146 |
| Leukemia | 3.4 | 206 | |
| Acute Lymphocytic Leukemia | 2.0 | 121 | |
| Brain and ONSd | 2.4 | 147 | |
| Hodgkin Lymphoma | 2.3 | 138 | |
| Non-Hodgkin Lymphoma | 2.1 | 124 | |
| Bones and Joints | 2.0 | 119 | |
| Age 16 | All Sites | 19.5 | 1,193 |
| Leukemia | 3.3 | 199 | |
| Acute Lymphocytic Leukemia | 2.0 | 123 | |
| Brain and ONSd | 2.5 | 152 | |
| Hodgkin Lymphoma | 2.5 | 151 | |
| Thyroid | 2.3 | 141 | |
| Non-Hodgkin Lymphoma | 1.4 | 86 | |
| Age 17 | All Sites | 23.3 | 1,444 |
| Hodgkin Lymphoma | 3.6 | 221 | |
| Leukemia | 3.1 | 190 | |
| Acute Lymphocytic Leukemia | 1.6 | 99 | |
| Thyroid | 2.6 | 164 | |
| Brain and ONSd | 2.5 | 153 | |
| Testise | 2.2 | 137 | |
| Age 18 | All Sites | 23.0 | 1,433 |
| Thyroid | 3.2 | 200 | |
| Hodgkin Lymphoma | 3.2 | 197 | |
| Leukemia | 3.0 | 187 | |
| Acute Lymphocytic Leukemia | 1.6 | 98 | |
| Testise | 2.9 | 178 | |
| Brain and ONSd | 1.8 | 114 | |
| Age 19 | All Sites | 25.9 | 1,603 |
| Thyroid | 3.9 | 244 | |
| Hodgkin Lymphoma | 3.7 | 231 | |
| Testise | 3.0 | 186 | |
| Leukemia | 2.7 | 168 | |
| Acute Lymphocytic Leukemia | 1.3 | 81 | |
| Brain and ONSd | 1.9 | 118 |
Footnotes:
a Rates are per 100,000 per year.
b Top 5 cancer sites were determined based on the 2009-2013 age-specific rate.
c SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).
d ONS = Other Nervous System. IBD = Intrahepatic Bile Duct.
e The rates for sex-specific cancer sites are calculated using the population for both sexes combined.
- Statistic not shown. Rate based on less than 16 cases for the time interval.
Page Navigation: << Previous Next >>
The information on this page is archived and provided for reference purposes only. Persons with disabilities having difficulty accessing information on this page may e-mail for assistance.